<DOC>
	<DOCNO>NCT00076401</DOCNO>
	<brief_summary>The purpose study determine drug motexafin gadolinium effective treatment patient chronic lymphocytic leukemia ( CLL ) come back treatment stop respond treatment .</brief_summary>
	<brief_title>A Study Motexafin Gadolinium Treatment Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Motexafin gadolinium</mesh_term>
	<criteria>At least 18 year old Refractory relapse CLL ECOG performance status score 0 , 1 , 2 Each patient must sign studyspecific inform consent form Laboratory value : Platelet count &lt; 30,000/uL AST ALT &gt; 2 x upper limit normal ( ULN ) Total bilirubin &gt; 2 x ULN Creatinine &gt; 2.0 mg/dL Chemotherapy , radiation therapy , immunotherapy , systemic corticosteroid , systemic biologic anticancer therapy within 21 day begin study treatment Women pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>CLL</keyword>
	<keyword>chronic lymphocytic leukemia</keyword>
	<keyword>relapse chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Motexafin gadolinium</keyword>
	<keyword>Chronic leukemia</keyword>
	<keyword>Lymphocytic leukemia , chronic</keyword>
</DOC>